Biotech Values

[DewDiligence]

IDRA reports final phase-1 HCV data for IMO-2125:

http://finance.yahoo.com/news/Idera-Pharmaceuticals-bw-1674592526.html?x=0&.v=1

This PR has slightly more detail than the one issued by IDRA in December (#msg-57983764).

IMO-2125 is a TLR9 agonist that being positioned as a replacement for interferon. However, the phase-1 data in this study were not clearly better in the IMO-2125 + ribavirin arms than in the SoC control arm. Moreover, the 0.16mg/kg weekly dose of IMO-2125 produced better results than either the 0.32mg/kg weekly dose or the 0.16mg/kg twice-weekly dose, a puzzling outcome.